Mesa Labs 8-K: Officer/Director Changes & Comp Arrangements
Ticker: MLAB · Form: 8-K · Filed: Jan 8, 2024 · CIK: 724004
| Field | Detail |
|---|---|
| Company | Mesa Laboratories Inc /Co/ (MLAB) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: officer-change, director-change, compensation, regulation-fd
TL;DR
**Mesa Labs just filed an 8-K about leadership changes and executive pay.**
AI Summary
Mesa Laboratories, Inc. filed an 8-K on January 8, 2024, reporting that the earliest event occurred on January 5, 2024. This filing primarily concerns the departure or election of directors or officers and their compensatory arrangements, as well as Regulation FD Disclosure. For investors, this matters because changes in leadership can signal strategic shifts or operational challenges, potentially impacting the company's future performance and stock value.
Why It Matters
Changes in executive leadership or director roles can significantly influence a company's strategic direction and operational stability, directly affecting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty, but the specific details of this filing are not yet public, making the immediate impact unclear.
Analyst Insight
A smart investor would monitor subsequent filings or press releases from Mesa Laboratories, Inc. for specific details regarding the personnel changes and compensatory arrangements, as these specifics will determine the actual impact on the company.
Key Players & Entities
- MESA LABORATORIES INC /CO/ (company) — the registrant filing the 8-K
- January 5, 2024 (date) — date of earliest event reported
- January 8, 2024 (date) — date the 8-K was filed
FAQ
What is the primary purpose of this 8-K filing by Mesa Laboratories, Inc.?
The primary purpose of this 8-K filing, as indicated by the 'ITEM INFORMATION', is to report on 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Regulation FD Disclosure'.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 5, 2024, as stated under 'Date of Report (Date of earliest event reported): January 5, 2024'.
What is the full legal name of the company filing this 8-K?
The full legal name of the company filing this 8-K is MESA LABORATORIES, INC., as specified in its charter.
What is Mesa Laboratories, Inc.'s business address and phone number?
Mesa Laboratories, Inc.'s business address is 12100 WEST SIXTH AVENUE, LAKEWOOD, Colorado, 80228, and its telephone number is 303-987-8000.
Under which SEC Act is this Form 8-K filed?
This Form 8-K is filed under the Securities Exchange Act of 1934, as indicated by 'Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934'.
Filing Stats: 799 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2024-01-08 08:00:17
Filing Documents
- mlab20240103_8k.htm (8-K) — 30KB
- ex_611846.htm (EX-99.1) — 7KB
- 0001437749-24-000821.txt ( ) — 169KB
- noticker-20240105.xsd (EX-101.SCH) — 3KB
- noticker-20240105_def.xml (EX-101.DEF) — 11KB
- noticker-20240105_lab.xml (EX-101.LAB) — 15KB
- noticker-20240105_pre.xml (EX-101.PRE) — 11KB
- mlab20240103_8k_htm.xml (XML) — 2KB
01 REGULATION FD DISCLOSURE
ITEM 7.01 REGULATION FD DISCLOSURE   A copy of the Company's press release announcing Mr. Capone's appointment is attached as Exhibit 99.1 to this Current Report on Form 8-K.   The information contained in Item 7.01 of this report and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.  
01 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS   (d) Exhibits   99.1 Press release dated January 8, 2024. 104 Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document (included as Exhibit 101)       SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     DATE: January 8, 2024       Mesa Laboratories, Inc.         (Registrant)                           BY:  /s/ Gary M. Owens           Gary M. Owens         President and Chief Executive Officer